Immuno-Oncology | Specialty

Dr. Julie Brahmer Explains the Role of PD-1 and PD-L1

September 13th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, explains the role of PD-1 and PD-L1.

Ipilimumab Fails to Prolong Survival in mCRPC

September 12th 2013

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab in men with metastatic castration-resistant prostate cancer failed to meet its primary endpoint of prolongation in overall survival.

Dr. Gulley Discusses Vaccine Responses

September 10th 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

Novel Agents Revolutionize Melanoma Treatment

September 5th 2013

Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-α (IFN-α).

Dr. Sosman on Immunotherapy in Melanoma and Renal Cancer

August 28th 2013

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Study Shows Benefit of High-Dose IL-2 in Melanoma Brain Metastases

August 23rd 2013

High doses of interleukin-2 could be used to treat patients with melanoma whose disease has metastasized to the brain, potentially expanding options in a population facing a grim prognosis.

Dr. Parsa on the Administration of the G-200 Vaccine in GBM

August 21st 2013

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.

Dr. Schuchter Discusses Nivolumab in Melanoma

August 21st 2013

Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Nivolumab Benefits Durable in Three Tumor Types

August 19th 2013

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Dr. Brahmer on the Future of Antibodies for Lung Cancer

August 16th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the future of antibodies, including nivolumab, for the treatment of lung cancer.

Experts Discuss Manipulation of T Cells for Therapy in Hematologic Malignancies

August 16th 2013

Finding new ways of manipulating the body's own defenses to better combat various hematologic malignancies is yielding some interesting results and could represent a very promising new field of care for patients dealing with these disorders.

Study Details Adverse Events in Pivotal Ipilimumab Trial

August 16th 2013

Adverse events associated with ipilimumab for the treatment of metastatic melanoma are better understood after further analysis of clinical trial data that led to the FDA's 2011 approval of the drug.

Dr. Carbone on Immunotherapy Research in Lung Cancer

August 15th 2013

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

Dr. Goy on Developments in the Field of Immunology

August 14th 2013

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, comments on the recent developments in fighting cancer with the immune system.

Immunotherapy Hits New Peak: ASCO Data Stir Excitement, Investment

August 14th 2013

Any lingering skepticism about immunotherapy as an anticancer strategy appears to have been banished by research presented at the 2013 ASCO Annual Meeting.

Allovectin Falters in Late-Stage Melanoma Trial

August 13th 2013

Nearly two decades after clinical trials began, the investigational immunotherapy Allovectin failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma and will no longer be developed.

ASCO 2013: Humanity Meets Immunity

August 13th 2013

While the anti-T-cell-checkpoint approach is far from perfect, the demonstrated ability for humanity to overcome evolutionary design and break tumor cell tolerance to turn the tide against cancer is nothing less than inspiring.

Dr. Saenger on the Need for Immunotherapy Biomarkers

August 7th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

Dr. Herbst on Immunotherapy in Lung Cancer

August 2nd 2013

Roy S. Herbst, MD, PhD, chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.

Dr. Ribas on the Efficacy of Ipilimumab in Melanoma

July 29th 2013

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.

NEXT PAGE
PREVIOUS PAGE